Abstract
Author(s): Huda Ali Mohammed*, Asma Abdul JaleelSwadi, Sinaa Abdul Amir Kadhim
Background: Anovulation and hyperandrogenism, in combination with ovarian morphological changes, insulin resistance, inappropriate secretion of gonadotropins and associated compensatory hyperinsulinaemia, remain hallmarks of PCOS, a most common endocrine disease that afflicts some women. Three groups of patients were identified: the M group (n=50) receiving metformin, the MS group (n=50) receiving metformin and spironolactone, and the S group (n=50) receiving spironolactone. According to the Rotterdam guidelines (Rotterdam, 2004), two obstetricians and gynaecologists diagnosed these patients with Polycystic Ovarian Syndrome (PMS). The patients were enrolled as of the Maternity and Pediatrics Teaching Hospital in Adiwaniyah Province, Iraq. The training is to start after September 1, 2024 and will last until March 1, 2025. Results: All three treatment modalities, metformin, spironolacto,and combination were able to reduce themesn (BMI), mean total testosterone and the mean Ferriman-Gallstone (FGS) score and to significantly increase the mean ghrelin and the mean adiponectin (p<0.001). The magnitude of the reduction in Body Mass Index (BMI), total testosterone and the magnitude of the increase in mean ghrelin and mean adiponectin were best while using the combination. Conclusion: Combination of spironolactone and metformin provide better approach for improving hirsutism out com in women with PCOS as evident from total testesteron concentration and (FGS)score in addition to improved levels of serum ghrelin and adiponectin.